The Woman’s Hospital of Texas now welcomes its newest arrival: The Pediatric Center
Linda Russell, CEO of The Woman’s Hospital of Texas, recently announced the opening of the Pediatric Center—located on the fifth floor of the hospital— now offering emergency, inpatient and intensive care services for children ages 17 years and
under. “The Woman’s Hospital of Texas has long been a leader in providing exceptional care to women and neonates,” said Linda Russell, CEO of The Woman’s Hospital of Texas.
“We are proud to expand that level of highquality care to include our youngest patients by opening the Pediatric Center.”Parent Susan Lopez delivered both her girls at The Woman’s Hospital of Texas. Lopez says, “I originally chose to have my babies at The Woman’s Hospital of Texas because this was the only hospital where my doctor would deliver babies. But if I had to make the choice again, I would still choose The Woman’s Hospital of Texas because of the exceptional care the staff provides, and now its new Pediatric Center offers the nurturing environment that moms want for their children.”
The staff will provide the same high quality, personalized, compassionate care to children that Houston women have received for nearly 40 years. Now, the hospital that delivers more babies than any other hospital in Houston will provide continuity of care for children from conception to adulthood. At nearly 24,000 square feet, the Pediatric Center will provide a separate, dedicated 6-bed emergency department, an 18-bed medical/surgical inpatient unit and a 14-bed pediatric intensive care unit. The Pediatric Center will provide an array of pediatric services, including emergency medicine, pediatric surgery and critical care services, along with a wide range of pediatric specialties for consultation and treatment, including cardiology, ENT, urology and others, by some of Texas’ finest boardcertified pediatric physicians. There will be a dedicated waiting room in the Emergency Department and a special children’s play room and a teen room on the medical/surgical inpatient unit. A kid-friendly menu will also be available.
Our goal is to be a resource that will direct people to the appropriate level of care andsetting – one that is conducive to helping patients get better.”
Modeled after the first clinic in Humble, this walk-in clinic provides rapid access to initial psychiatric treatment and outpatient multi-disciplinary services for patients with no immediate access to mental health care. The idea is to keep individuals healthy and safe, develop processes and interventions to manage challenging behaviors, and reduce improper hospitalization or incarceration.
Last year, the Memorial Hermann more than 6,200 evaluations and found increasingly complicated co-occurring medical and psychiatric disorders, few available inpatient psychiatric beds, even fewer inpatient options to treat complex cooccurring disorders, and limited outpatient services to meet patient needs.
Using 14 years of data from 10 Memorial Hermann emergency rooms and valuable input from law enforcement, personal care homes, consumer representatives, other area psychiatric hospitals, and public and private community behavioral health services providers; Memorial Hermann will identify the locations for the two remaining clinics in key underserved areas.
Harris County Sheriff Adrian Garcia has supported the move to create more mental health resources saying previously that: “We must move away from a crisis-based system that leaves our law enforcement officers, our jails, and our emergency rooms as defacto mental health providers. With more than 25 percent of the approximately 9,000 inmates on psychotropic medication, I’m running the state’s largest mental health facility- the Harris County Jail. There must be a better solution, and I applaud Memorial Hermann for its efforts to be part of that solution.”
HCA Gulf Coast Division breaks ground on Pearland Medical Center
HCA Gulf Coast Division President Maura Walsh, along with Pearland Mayor Tom Reid, Manvel Mayor Delores Martin, HealthOne 24 Hour Emergency Care – Pearland Medical Director Earl Miller, M.D., and HCA Gulf Coast Division Chief Financial Officer, Jeff Sliwinski recently broke ground for the new $71 million Pearland Medical Center.
“The Pearland Medical Center groundbreaking emphasizes HCA Gulf Coast Division’s long-standing commitment to the residents of Pearland and Brazoria County by providing convenient, highquality healthcare close to home,” Walsh said. “As an HCA affiliated hospital, Pearland Medical Center joins our continuum of nine other Houston - area medical centers, ambulatory surgery centers, diagnostic imaging facilities, and off campus emergency centers.”
The 144,000-square-foot, 30-bed acutecare hospital will open in the fall of 2014 and feature surgical suites, medical/surgical beds, intensive care beds and a 24-hour emergency department. Imaging services will include magnetic resonance imaging, computerized tomography, a catheterization lab, echocardiogram testing, and nuclear medicine modalities. The Center’s new women’s services will provide digital mammography, labor and delivery suites, cesarean-section operating rooms and a newborn nursery.
The new hospital will be located at the southwest intersection of Highway 288 and Shadow Creek Parkway on a 48-acre site currently home to a full-service, freestanding emergency department, imaging center and 3-story, 80,000 square foot medical office building. Construction is scheduled to start in October. ▼
Memorial Hermann Health System announces $93 million expansion of Its Sugar Land Hospital
Memorial Hermann Health System recently announced a $93 million expansion and upgrade of its Memorial Hermann Sugar Land hospital into the area’s most advanced facility.
The expansion to Memorial Hermann Sugar Land hospital is designed to significantly enhance the patient experience and meet the healthcare needs in the rapidly growing Fort Bend County region. When complete, the expansion will include a new six-story, 120,000-square-foot patient tower that will increase the hospital’s total bed count to 141, as well as an additional professional building, new equipment and related facilities.
“One of our highest priorities is to prepare for the growing market in Fort Bend County,” said Dan Wolterman, President and CEO of Memorial Hermann Health System.
“With the expansion of our Sugar Land h o s p i t a l , along with major nearby f a c i l i t i e s in our Southwe s t , Katy and T e x a s Medical Center hospitals, we will be wellprepared to fully serve all of the residents of Fort Bend County,” said Wolterman.
Phase one of the project will see eight new beds added to the Emergency Center, increasing the total to 26, and the building of a new surgical suite with full digital integration affording surgeons access to patients’ records and imaging studies within the operating room. Shell space will also be added to accommodate future surgical suites. A new MRI and an advanced CT scanner will technologically upgrade the hospital’s imaging capabilities. Phase one is expected to begin later this year and be completed by mid- 2014.
“Sugar Land and the surrounding area continue to grow and it is our responsibility to respond to that growth not only with upgraded and expanded facilities, but also with new technology and a higher level of services,” said Greg Haralson, CEO of Memorial Hermann Sugar Land Hospital.
Phase two of the project, expected to break ground in November 2014, will add a second professional office building. The new structure will provide 100,000 square feet of combined physician offices, expanded sports medicine and rehabilitation services, along with outpatient imaging.
Construction on the patient tower will begin around the same time, in the fall 2014, marking phase three of the expansion. When completed, the intensive care unit bed count will increase to 14, and 16 new beds will be added to the intermediate care unit. Including shell and expansion capability, the tower will ultimately house 210 beds.
“We continue to invest in our future to meet the growing needs of our community,” Haralson continued. “We are well on our way to accomplishing our vision to bring a medical center level of care to the communities we serve.”
This is the first major development project undertaken at Memorial Hermann Sugar Land since its opening in 2006.
The expansion plans for Memorial Hermann Sugar Land hospital comes on the heels of major growth initiatives at Memorial Hermann The Woodlands, Memorial Hermann Katy, Memorial Hermann Northwest hospitals, and development of a medical campus in Pearland that will feature a Convenient Care Center, a 64-bed hospital and medical office buildings.
Expansion details at a glance:
• $93 million project in 3 phases
• 100,000 square foot professional office building
• 120,000 square foot patient tower
• Emergency Center expanding capacity to 26 beds
• New MRI and upgraded CT scanner
• ICU beds to increase to 14
Planning to avoid or minimize the 3.8% net investment income tax
BY REED TINSLEY, CPA, CVA, CFP, CHBC
As you know, the new 3.8% Medicare tax on net investment income, which we I call the NIIT, is effective for tax years beginning on or after 1/1/13. In this article, I will cover some planning ideas that may allow individual taxpayers to avoid or minimize the NIIT. Since year-end is not too far away, you can include these ideas with your other yearend tax planning strategies.
Net Investment Income Tax (NIIT) basics
Before jumping into the planning strategies, let’s first rehash the basics. An individual is only hit with the NIIT when his or her Modified Adjusted Gross Income (MAGI) exceeds $200,000 for an unmarried taxpayer, $250,000 for a married joint-filing couple or a qualifying widow or widower, or $125,000 for married filing separate couples. The amount actually subject to the NIIT is the lesser of: (1) net investment income or (2) the amount by which MAGI exceeds the applicable threshold. For this purpose, MAGI is AGI plus certain excluded foreignsource income of U.S. citizens and residents living abroad net of certain deductions and exclusions.
The following types of income and gain (net of related deductions) are generally included in the definition of net investment income and, thus, potentially exposed to the NIIT:
• Net gain from selling assets held for investment-including gains from selling investment real estate and the taxable portion of gain from selling a personal residence. • Capital gain distributions from mutual funds.
• Gross income from interest (not including tax-free interest such as municipal bond interest), dividends, royalties, and annuities.
• Gross income and net gain from passive business activities (meaning business activities in which the taxpayer does not materially participate) and gross income from rents.
• Net gain from selling partnership and S corporation interests held for investment.
• Gross income and gain from the business of trading in financial instruments or commodities (whether the taxpayer materially participates or not).
Setting the proper target for NIIT planning strategies
As explained earlier, the NIIT for individual taxpayers hits the lesser of: (1) net investment income or (2) the amount by which MAGI exceeds the applicable threshold. Therefore, planning strategies will be effective only if they target the applicable exposure point.
If net investment income is the lower number (i.e., net investment income is less than MAGI), your NIIT exposure will mainly depend on your net investment income. So planning should focus first on strategies that reduce net investment income. Of course, some of these strategies will also reduce AGI.
If MAGI is the lower number, your NIIT exposure will mainly depend on your AGI. So planning should focus first on strategies that will reduce AGI. Of course, here too, some of these strategies will also reduce net investment income.
Specific strategies to reduce this year’s net investment income
Here are few ideas to reduce net investment income:
• Selling loser securities held in taxable brokerage firm accounts to offset earlier gains from such accounts. (This will also reduce AGI.)
• Gifting soon-to-be-sold appreciated securities to children and letting them sell them to avoid including the gains on the parent’s return. (This will also reduce the parent’s AGI.) But beware of the Kiddie Tax, which can potentially cause children under age 24 to pay taxes at their parent’s higher rates. However, as long as the investment income is reported on the child’s return (i.e., the parents don’t elect to include it on their return), it won’t be subject to the NIIT unless the child’s MAGI exceeds his or her applicable threshold.
• Utilizing an installment sale to spread a big investment gain over several years. (This will also reduce AGI.)
• Instead of cash, gifting appreciated securities to IRS-approved charities. That way, the gains won’t be included on the donor’s return. (This will also reduce the donor’s AGI.)
These are just a few ideas for reducing or avoiding the NIIT – there are others. Some ideas take time to implement so start discussing this issue with your tax advisor now if you think you might be subject to this new tax this year. ▼
OCR posts last minute guidance for implementation of Omnibus Rule
By Mary M. Bearden and Allison Shelton , Brown & Fortunato , P.C.
During the month of September, the Office for Civil Rights (OCR) posted several implementation guides for health care providers that qualify as covered entities under the Health Insurance Portability and Accountability Act (HIPAA). These guides were posted as an effort to assist covered entities in implementing provisions of the Omnibus Health Insurance Portability and Accountability Act Final Rule (Omnibus Rule) that went into effect on September 23, 2013. Even though the Omnibus Rule was first published on January 25, 2013, OCR waited until September to issue guidance for covered entities.
Over the month of September, OCR posted guidance for drafting Notices of Privacy Practices (NPPs), applying HIPAA protections to decedents, issuing refill reminders, and preparing for emergency situations. This article provides an overview of OCR’s guidance regarding NPPs and refill reminders.
NPPs enable individuals to be informed of their privacy rights under HIPAA and of the covered entity’s practices that relate to those rights. Because the Omnibus Rule made several changes to the HIPAA Privacy Rule, covered entities were required to modify their NPPs by September 23, 2013. Specifically, according to the Omnibus Rule, health care providers should have added statements indicating the following: (1) The covered entity’s use or disclosure of the individual’s protected health information (PHI) for marketing purposes requires the individual’s written authorization. (2) A disclosure that constitutes the sale of PHI requires the individual’s written authorization. (3) The covered entity may contact the individual to raise funds for the covered entity, and the individual has a right to opt out of receiving such communications. If the covered entity does not engage in any fundraising, however, then the entity is not required to insert this information into the NPP. (4) Generally, a covered entity is not required to agree to restrictions on certain uses and disclosures of PHI requested by an individual. However, in the event a patient requests a restriction on payment or health care operational disclosures to a health plan about items paid in full by the individual, the covered entity must comply with the restriction as long as the disclosure is not required by law. (5) The covered entity is required by law to notify affected individuals following a breach of unsecured PHI.
On September 13, 2013, OCR and the Office of the National Coordinator for Health Information Technology developed and published model language for the NPPs of health care providers and health plans. The model language is provided in various formats that a covered entity may customize and distribute.
Six days later, on September 19, 2013, OCR released guidance entitled, “The HIPAA Privacy Rule and Refill Reminders and Other Communications about a Drug or Biologic Currently Prescribed for the Individual.” This guidance concerns the new definition of “marketing” adopted in the Omnibus Rule.
Generally, a covered entity may not use or disclose an individual’s PHI for marketing purposes unless the individual has authorized the communication in writing. Under the HIPAA rules, marketing is defined as a communication that encourages the recipient to use or purchase a product or service. At times, such communications are necessary for treatment and health care purposes; therefore, certain exceptions apply to the marketing definition, including refill reminders or other communications about a currently prescribed drug or biological, when the covered entity receives “financial remuneration . . . [that] is reasonably related to the . . . cost of making the communication. OCR’s guidance breaks down the elements of the refill reminder exception and provides clarification on a number of scenarios that are potentially affected by the exception.
Several covered entities in the industry awaited this guidance because of a suit filed by Adheris Inc., against the Department of Health and Human Services on September 5, 2013. Adheris contracts with pharmacies to provide refill reminders and medication adherence messages to patients. These communications are paid for by pharmaceutical companies. Therefore, under the changes adopted in the Omnibus Rule, the messages could qualify as prohibited marketing communications unless the patients authorized the communications in writing or the “financial remuneration . . . is reasonably related to the . . . cost of making the communication.” Claiming that the restrictions on marketing communications violate the First Amendment, Adheris sought a preliminary injunction. In a response filed on September 11, 2013, HHS asked the court to suspend proceedings and indicated that guidance regarding reasonable financial remuneration for refill reminders would be released by September 23, 2013.
In the guidance posted on September 19, 2013, OCR discusses (1) payments from a third party to a covered entity for refill reminders; (2) payments from a covered entity to a business associate when a third party directly or indirectly covers the payments to the business associate; and (3) payments from a covered entity to a business associate when no third party is involved. In the first case, the third party may only cover the direct and indirect costs related to the refill reminder. For example, the third party may pay reasonable costs related to labor, supplies, materials, overhead and capital expenditures. In the second case, when a business associate receives remuneration directly or indirectly from the third party, the third party may pay fair market value for the business associate’s services. This is the case under Adheris’ business model. Finally, in the third case, the exception for refill reminders will not limit the financial remuneration that the covered entity may pay the business associate because no third party is involved.
Even though OCR’s information concerning reasonable financial remuneration was the most anticipated aspect of the guidance, clarification for other interesting scenarios is also provided in the guidance. For example, various messages can qualify for the refill reminder exception, including information about generic equivalents of the prescribed drug; communications about prescriptions that have lapsed within the last ninety calendar days; and communications encouraging individuals to take medications as directed. Also, if a drug is administered through durable medical equipment (DME), such as an insulin pump or a nebulizer, then the refill reminder exception will encompass “communications regarding all aspects of the drug delivery system,” including the DME.
Other communications will not qualify for the exception, including communications about new formulations of the prescribed drug; information about adjunctive drugs that may be used along with the currently prescribed drug; and messages encouraging the recipient to switch to an alternative medicine. Such communications may qualify for the treatment exception, however, as long as the covered entity does not receive financial remuneration for the communication. Also, OCR indicates that covered entities may communicate with the individual about new formulations and adjunctive drugs in a general manner and without naming the actual drug. For example, a pharmacy may encourage an individual to speak with his or her doctor about medications that may treat the side effects of a currently prescribed drug.
When a covered entity obtains an individual’s written authorization for communications funded by a pharmaceutical manufacturer, OCR indicates that a new authorization is not required for each new prescription. HIPAA compliant authorizations must include an expiration date or event. According to the Refill Guidance, this requirement may be met if the authorization expires when the individual opts out of receiving the authorized communication. Moreover, the scope of the authorization need not be limited to a single drug or biological or to a single pharmaceutical manufacturer.
In addition to posts concerning NPPs and refill reminders, OCR has provided guidance on applying HIPAA protections to decedents and on preparing for emergency situations. Hospitals, physicians, and other covered entities should visit HHS.gov to ensure that their policies, procedures, and forms are consistent with OCR’s guidance. ▼
UH’s Contreras-Vidal, NASA work on a rehab robot patients control with their brain
Jose Luis Contreras-Vidal looked on as Roger Rovekamp, wearing a skullcap covered in electrodes, took halting steps, each leg moved by the robotic exoskeleton wrapped around his body.
Contreras-Vidal, a professor of electrical and computer engineering at the University of Houston Cullen College of Engineering, develops algorithms that read electrical activity in the brain and translate it into movement.
His Rehab Rex gained attention for its ability to help people with spinal cord injuries stand upright and “walk.” That project is now waiting for clinical testing to begin at Houston Methodist Hospital.
His newest project is a collaboration with engineers from NASA, and it could help patients with conditions such as stroke or Parkinson’s disease. Contreras-Vidal said at least some of those patients would use the robot only temporarily, as a rehabilitation tool.
Rovekamp, a robotics engineer with Oceaneering Space Systems, recently served as a test subject on the new project. He said NASA wants to address the muscle atrophy and other health risks astronauts might face during long-duration space travel.
The X1 exoskeleton was jointly designed by NASA and the Florida Institute for Human and Machine Cognition in Pensacola, Fla.
NASA is interested in its potential as an exercise tool for crew members, both at the International Space Station and on future long-duration space flights, and Contreras- Vidal said the X1 also could have the ability to measure and send data back to flight controllers, providing information on how the flight is affecting their health.
But much of his research is focused on the exoskeleton’s potential for use in physical therapy. The X1 is smaller than the Rehab Rex and could help people recover from a brain injury by teaching the brain to re-wire itself, he said.
The brain-machine interface, or BMI, technology works by interpreting brain waves that allow patients to control the robotic legs with their thoughts. It can control the user’s movements, through motorized joints at the hips and knees, or simply provide some resistance, depending on how it is programmed, he said.
Contreras-Vidal and his research team record brain signals using a scalp electroencephalogram, or EEG, through a skullcap fitted with electrode sensors. That avoids the need for implanting electrodes under a patient’s scalp.
The electrodes also can measure brain activity to ensure the patient is actively mentally engaged in the rehab, he said. That’s important, “because you want to eventually get rid of the robot. You want to retrain the brain, so the patient has to be actively engaged.”
Children’s Medical Center launches first neonatal telemedicine program in Texas
Children’s Medical Center of Dallas recently announced it is launching the state’s first dedicated neonatal telemedicine program— the Children’s Medical Center TeleNICU. The new service will provide physicians at other hospital neonatal intensive care units (NICUs) with 24-hour access to the highly trained, board-certified UT Southwestern neonatologists on Children’s medical staff in order to consult on care for the region’s tiniest and most fragile patients.
The TeleNICU program utilizes specialized equipment and secure broadband transmission to allow two-way, real-time interactive communication between hospitals and enable expert neonatologists at Children’s to virtually examine newborns at distant-site NICUs. Participating hospitals will connect to Children’s through a mobile equipment cart that includes medical-quality videoconferencing, data transfer and digital scoping equipment. Children’s Medical Center TeleNICU will be fully operational this month and ready to assist other hospital NICUs located in Texas and beyond.
“As the first telemedicine program of its kind in Texas, the Children’s Medical Center TeleNICU program exemplifies our deep commitment to innovation and the use of proven technology to extend the reach of our expertise beyond the boundaries of walls and geography,” said Christopher J. Durovich, president and chief executive officer of Children’s.
Affiliated with UT Southwestern Medical Center, one of the nation’s leading academic medical institutions, Children’s is the only pediatric teaching and research hospital in North Texas. As the region’s major neonatal tertiary-care center, Children’s provides complex care for seriously ill newborns and infants transferred from other hospitals.
According to Durovich, the NICU at Children’s is designated a Level-IV—the highest standard set by the American Academy of Pediatrics—and staffed 24/7 by expert UT Southwestern neonatologists.
Although the total number of hospital NICUs in Texas and nationally has increased over the past decade, many are Level-I and Level-II NICUs that are not staffed or equipped for complex care. The Children’s Medical Center TeleNICU program can help facilitate sound decision-making in the region about whether and when transfers are necessary, which is intended to result in both improved care and reduced cost. The hope is that TeleNICU consultation will minimize or even eliminate the need for transport in many cases, so newborns can remain at their home hospitals longer— reducing the stress of travel on both patients and families.
The Children’s Medical Center TeleNICU also is expected to play an important regional role in ongoing provider education and quality care by facilitating greater flow of information and expertise among health care providers, and accomplishing it more efficiently.
“As a Level-IV NICU and a major academic and research center, we have a responsibility to import and export best practices and share established protocols with other hospitals – and telemedicine enables us to be available without the constraints of physical travel,” said Dr. Rashmin Savani, division director of neonatal-perinatal medicine at UT Southwestern and Children’s, and professor of pediatrics at UT Southwestern Medical Center.
Savani also pointed out that North Texas has a growing population with a climbing birthrate, in contrast to other parts of the country, and the demand for NICUs remains high due to premature deliveries and multiple births, among other factors.
“The Children’s Medical Center TeleNICU will enhance the quality of neonatal intensive care in our region today, as well as prepare for the future pediatric population in the communities we serve,” said Savani. Former US Oncology executives to lead U.S. launch of genetic diagnostic platform.
In anticipation of the launch of its CLIAcertified genetic diagnostic platform for cancer care, MolecularHealth announced that it has opened North American offices in The Woodlands, Texas and appointed a new management team, headed by Lloyd Everson, M.D., CEO of the U.S. division. Dr. Everson is joined by three fellow US Oncology veterans: Marc Kerlin, Chief Operating Officer; Philip Watts, General Counsel; and Chet Dye, Chief Development Officer.
Dietmar Hopp, co-founder and former chairman and CEO of SAP, and the lead investor in MolecularHealth, said, “When we founded SAP forty years ago, we believed that organizing previously disaggregated data and systems could make for more efficient, effective resource planning. Today I see a similar opportunity in the healthcare sector, and MolecularHealth is paving the way through the integration of clinical and molecular information.”
In the first half of 2014, the company expects to launch its integrated service offering, which includes a CLIA-based next generation sequencing laboratory and a unique analytics platform that generates safer and targeted treatment choices for cancer patients and their physicians, based on integration of patients’ clinical and genetic information with the world of biomedical and molecular knowledge. As part of its offering, MolecularHealth will provide patients, oncologists and pathologists with complete logistical support, including navigating insurance reimbursement.
“MolecularHealth’s computational and diagnostic platform is the result of more than eight years of development by a multidisciplinary team of doctors, scientists and IT experts,” said Friedrich von Bohlen, Ph.D., chairman of the board of directors for MolecularHealth. “This management team brings with it the medical and operational experience needed to commercially launch MolecularHealth here in North America, and to make our cancer diagnostics offering available to oncologists, pathologists, patients and their families.”
Chief Executive Officer U.S. Division Dr. Everson, who previously served as vice chairman and member of the board of directors of US Oncology, Inc., brings more than four decades of experience in oncology and hematology practice and research to his role at MolecularHealth. Dr. Everson, who earned a medical degree from Harvard Medical School, has held clinical and research positions at Cornell Medical Center, Memorial Sloan Kettering Cancer and the National Cancer Institute. He also served as President and Chief Operating Officer of American Oncology Resources, Inc., the predecessor organization of US Oncology. In 2009, Dr. Everson formed the Life Beyond Cancer Foundation, a nonprofit serving the needs of cancer survivors, where he serves as chairman of the board.
Chief Operating Officer Marc Kerlin comes to MolecularHealth with 28 years of healthcare experience, most recently serving as President and Chief Executive Officer at e+Cancer Care, where he remains a member of the board of directors. Kerlin held several positions during his time at US Oncology, ultimately becoming Senior Vice President of Business Development, Marketing and Managed Care.
Philip Watts, MolecularHealth’s General Counsel, has spent a majority of his legal career focused on the oncology and healthcare space. At US Oncology, Watts served as Executive Vice President, General Counsel and Secretary, from 1997 until 2009. Before joining the team at MolecularHealth, he was Executive Vice President at U.S. Physiatry, LLC, where he was brought on to assist with developing the company’s business plan, recruiting a management team, and forming the company.
Chief Development Officer and Senior Vice President Chet Dye has spent 24 years driving business growth for companies focused on healthcare and oncology. Dye joined US Oncology in 1997 as a regional director and rose to become Vice President of Business Development and Physician Recruiting. He continued to work with US Oncology after it was acquired by McKesson, serving as National Vice President responsible for business development, sales, account management & physician recruiting. Immediately prior to joining MolecularHealth, he was Chief Development Officer at Solis Women’s Health, the largest independent provider of breast diagnostic services in the U.S.
“Genes are the fingerprints of life, and our CLIA-based, automated platform translates that genetic language into the best possible treatment according to a patient’s own genetic makeup, past medical history, and the best available scientific information and clinical research,” said Dr. Everson. “The installment of this team moves us forward on our path to revolutionizing how we view, understand and treat the onset and progression of cancer, in order to improve safety, efficacy and outcomes.” ▼